C Sotiriou

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. ncbi request reprint Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
  2. pmc Multiple-input multiple-output causal strategies for gene selection
    Gianluca Bontempi
    Machine Learning Group, Computer Science Department, Universite Libre de Bruxelles, Belgium
    BMC Bioinformatics 12:458. 2011
  3. pmc Loss, mutation and deregulation of L3MBTL4 in breast cancers
    Lynda Addou-Klouche
    Marseille Cancer Research Center, Department of Molecular Oncology, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Mol Cancer 9:213. 2010
  4. pmc A fuzzy gene expression-based computational approach improves breast cancer prognostication
    Benjamin Haibe-Kains
    Functional Genomics and Translational Research Unit, Medical Oncology Department, Jules Bordet Institute, boulevard de Waterloo, Brussels, 1000, Belgium
    Genome Biol 11:R18. 2010
  5. pmc Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
  6. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
  7. pmc Comparison of prognostic gene expression signatures for breast cancer
    Benjamin Haibe-Kains
    Functional Genomics Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Genomics 9:394. 2008
  8. pmc Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
    Jérôme Toussaint
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 10:424. 2009
  9. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
  10. pmc Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
    Qiyuan Li
    Center for Biological Sequence Analysis, Department of Systems Biolology, Technical University of Denmark, 2800 Lyngby, Denmark
    BMC Bioinformatics 12:310. 2011

Detail Information

Publications85

  1. ncbi request reprint Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer
    Marc Buyse
    International Drug Development Institute, Brussels, Belgium
    J Natl Cancer Inst 98:1183-92. 2006
    ..A 70-gene signature was previously shown to have prognostic value in patients with node-negative breast cancer. Our goal was to validate the signature in an independent group of patients...
  2. pmc Multiple-input multiple-output causal strategies for gene selection
    Gianluca Bontempi
    Machine Learning Group, Computer Science Department, Universite Libre de Bruxelles, Belgium
    BMC Bioinformatics 12:458. 2011
    ..In this study, we show how to efficiently incorporate causal information into gene selection by moving from a single-input single-output to a multiple-input multiple-output setting...
  3. pmc Loss, mutation and deregulation of L3MBTL4 in breast cancers
    Lynda Addou-Klouche
    Marseille Cancer Research Center, Department of Molecular Oncology, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    Mol Cancer 9:213. 2010
    ..Many alterations are involved in mammary oncogenesis, including amplifications of oncogenes and losses of tumor suppressor genes (TSG). Losses may affect almost all chromosome arms and many TSGs remain to be identified...
  4. pmc A fuzzy gene expression-based computational approach improves breast cancer prognostication
    Benjamin Haibe-Kains
    Functional Genomics and Translational Research Unit, Medical Oncology Department, Jules Bordet Institute, boulevard de Waterloo, Brussels, 1000, Belgium
    Genome Biol 11:R18. 2010
    ..In systematic evaluations, GENIUS significantly outperformed current gene signatures and clinical indices in the global population of patients...
  5. pmc Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures
    Pratyaksha Wirapati
    Swiss Institute of Bioinformatics, Batiment Genopode, University of Lausanne, 1015 Lausanne, Switzerland
    Breast Cancer Res 10:R65. 2008
    ....
  6. pmc Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Lab, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
    BMC Med Genomics 2:37. 2009
    ..CONCLUSION: These data demonstrate that activation of GF signaling pathways, independent of HER2 over-expression, could be contributing to the poor prognosis of the luminal-B ER+ BC subtype...
  7. pmc Comparison of prognostic gene expression signatures for breast cancer
    Benjamin Haibe-Kains
    Functional Genomics Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Genomics 9:394. 2008
    ..However, signatures were never compared on an independent population of untreated breast cancer patients, where risk assessment was computed using the original algorithms and microarray platforms...
  8. pmc Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues
    Jérôme Toussaint
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 10:424. 2009
    ....
  9. pmc Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
    Sherene Loi
    Functional Genomics Unit, Jules Bordet Institute, Brussels, Belgium
    BMC Genomics 9:239. 2008
    ..Independent validation was performed using 362 tamoxifen-treated ER+ BC samples obtained from multiple institutions and treated with tamoxifen only in the adjuvant and metastatic settings...
  10. pmc Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response
    Qiyuan Li
    Center for Biological Sequence Analysis, Department of Systems Biolology, Technical University of Denmark, 2800 Lyngby, Denmark
    BMC Bioinformatics 12:310. 2011
    ..However, identification of clinically predictive or prognostic classifiers can be challenging when a large number of genes are measured in a small number of tumors...
  11. pmc The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial
    Christine Desmedt
    Institut Jules Bordet, , Brussels, Belgium
    BMC Med Genomics 2:40. 2009
    ..Validation of these results, in a larger series from BIG 1-98, is planned using the simplified GGI represented by a smaller set of genes and tested by qRT-PCR on paraffin-embedded tissues...
  12. pmc Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer
    Christos Sotiriou
    Division of Clinical Sciences, Advanced Technology Center, National Cancer Institute, National Institutes of Health, Gaithersburg, USA
    Breast Cancer Res 4:R3. 2002
    ..Our goal was to determine the feasibility of obtaining representative expression array profiles from limited amounts of tissue and to identify those expression profiles that correlate with treatment response...
  13. ncbi request reprint Molecular profiling of head and neck tumors
    C Sotiriou
    Translational Unit, Jules Bordet Institute, Brussels, Belgium
    Curr Opin Oncol 16:211-4. 2004
    ..This article reviews recently reported studies that have used such approaches...
  14. ncbi request reprint Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis
    Christos Sotiriou
    Functional Genomics and Translational Research Unit, Universite Libre de Bruxelles, Brussels, Belgium
    J Natl Cancer Inst 98:262-72. 2006
    ..We examined whether histologic grade was associated with gene expression profiles of breast cancers and whether such profiles could be used to improve histologic grading...
  15. doi request reprint Gene profiling assay and application: the predictive role in primary therapy
    Debora Fumagalli
    Breast Cancer Translational Research Laboratory, Faculty of Medicine, Universite Libre de Bruxelles, Institut Jules Bordet, Bruxelles 1000, Belgium
    J Natl Cancer Inst Monogr 2011:124-7. 2011
    ....
  16. ncbi request reprint Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer
    V Durbecq
    Translational Research Unit, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Int J Oncol 25:1473-9. 2004
    ..Although the great majority of topo-II gene aberrations occur in HER-2 positive tumors, the level of HER-2 amplification does not predict for topo-II amplification...
  17. pmc Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
    E de Azambuja
    Medical Oncology Clinic, Jules Bordet Institute, 125 Boulevard de Waterloo, 1000, Brussels, Belgium
    Br J Cancer 96:1504-13. 2007
    ..65-3.91); P<0.001) and node-positive patients (HR=2.33 (95% CI: 1.83-2.95); P<0.001). Our meta-analysis suggests that Ki-67/MIB-1 positivity confers a higher risk of relapse and a worse survival in patients with early BC...
  18. ncbi request reprint Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers
    Amir A Jazaeri
    Laboratory of Biosystems and Cancer, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:6300-10. 2005
    ..The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in epithelial ovarian carcinoma...
  19. doi request reprint Genomic grade adds prognostic value in invasive lobular carcinoma
    O Metzger-Filho
    Breast Cancer Translation Research Laboratory J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:377-84. 2013
    ..Genomic grade (GG) is a 97-gene signature that improves the prognostic value of HG. This study evaluates whether GG may overcome the limitations of HG in ILC...
  20. doi request reprint A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics
    V Durbecq
    Translational Research Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Crit Rev Oncol Hematol 67:80-92. 2008
    ....
  21. doi request reprint Aiming at the target: improved adjuvant medical therapy
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Rue Heger Bordet 1, Brussels, Belgium
    Breast 18:S25-30. 2009
    ..It is hoped that coupling prospective biomarker discovery with new drug development in earlier stages of disease will yield additional targets that can be used to guide clinical decision-making in the future...
  22. ncbi request reprint Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes
    M Lacroix
    Laboratoire Jean Claude Heuson de Cancérologie Mammaire, Institut Jules Bordet, Free University of Brussels, Brussels, Belgium
    Oncol Rep 12:701-7. 2004
    ....
  23. pmc A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?
    B Haibe-Kains
    Machine Learning Group, Department of Computer Science, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Bioinformatics 24:2200-8. 2008
    ..The aim of this work is to assess quantitatively the accuracy of prediction obtained with state-of-the-art data analysis techniques for BC microarray data through an independent and thorough framework...
  24. ncbi request reprint The use of gene-expression profiling to better understand the clinical heterogeneity of estrogen receptor positive breast cancers and tamoxifen response
    Sherene Loi
    Translational Unit, Microarray Laboratories and Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Crit Rev Oncol Hematol 61:187-94. 2007
    ....
  25. ncbi request reprint Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
    Virginie Durbecq
    Jules Bordet Institute, 125 Boulevard de Waterloo, 1000 Brussels, Belgium
    Mol Cancer Ther 3:1207-14. 2004
    ..The predictive value of topoisomerase-II alpha (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel...
  26. ncbi request reprint What clinicians need to know about antioestrogen resistance in breast cancer therapy
    Amalia Milano
    Medical Oncology and Translational Research Unit, Jules Bordet Institute, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
    Eur J Cancer 42:2692-705. 2006
    ..Other predictive markers of tamoxifen-resistance/response, such as cyclin E and UPA/PAI-1, are also discussed...
  27. ncbi request reprint New data on chemotherapy in the adjuvant setting
    M J Piccart
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Breast 12:373-8. 2003
    ..The 3-year results of this trial strongly support concept 1; a longer follow-up and a confirmation study are desirable before recommending changes in routine patient care...
  28. ncbi request reprint Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases
    C Sotiriou
    Laboratory of Endocrinology/Bone Metabolism and Breast Cancer Research, Institut Jules Bordet, boulevard de Waterloo, 127B-1000, Brussels, Belgium
    Cancer Lett 169:87-95. 2001
    ..Our findings demonstrate for the first time IL-11 gene expression in some primary invasive breast tumors and suggest the potential of this cytokine as possible biological predictive factor for the development of bone metastases...
  29. ncbi request reprint Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers
    Amir A Jazaeri
    Division of Clinical Sciences of the National Cancer Institute, Gaithersburg, MD, USA
    J Natl Cancer Inst 94:990-1000. 2002
    ....
  30. doi request reprint Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH
    Christine Desmedt
    Department of Medical Oncology, Jules Bordet Institute, Brussels
    Diagn Mol Pathol 18:22-9. 2009
    ..27 (HER2:HER2 dimers)]. These data suggest that more quantitative or functional measurements of HER2 status may facilitate the development of more personalized treatment strategies for patients with metastatic breast cancer...
  31. doi request reprint Pertuzumab: new hope for patients with HER2-positive breast cancer
    M Capelan
    Department of Medicine, Institute Jules Bordet, l Université Libre de Bruxelles, Brussels, Belgium
    Ann Oncol 24:273-82. 2013
    ..Pertuzumab is a new anti-HER2 humanized monoclonal antibody that prevents the formation of HER2 dimers...
  32. doi request reprint Adjuvant chemotherapy--yes or no? Prognostic markers in early breast cancer
    M J Piccart-Gebhart
    Department of Medicine, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 18:xii2-7. 2007
    ..Close collaboration between clinicians and scientists will be essential to achieve this goal...
  33. doi request reprint Treatment tailoring based on molecular characterizations
    P Dinh
    Medical Oncology Department, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Belgium
    Ann Oncol 19:vii46-50. 2008
  34. doi request reprint Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients
    Fabrice Journe
    Laboratory of Endocrinology and Translational Research Unit, Department of Internal Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Breast Cancer Res Treat 115:523-35. 2009
    ..These results suggest that ER-positive breast tumors could be stimulated to proliferate via a crosstalk between FXR and ER, particularly in a state of estrogen deprivation (menopause, aromatase inhibitors)...
  35. ncbi request reprint The evolution of treatment strategies: aiming at the target
    Phuong Dinh
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre De Bruxelles U L B, 121 Blvd de Waterloo, 1000 Brussels, Belgium
    Breast 16:S10-6. 2007
    ..This paper will review this evolution of treatment strategies, from the lessons learnt from the past, to the exciting promise of tailored therapy of the future...
  36. ncbi request reprint Bringing molecular prognosis and prediction to the clinic
    Mariantonietta Colozza
    S C Oncologia Medica, Azienda Ospedaliera, Perugia, Italy
    Clin Breast Cancer 6:61-76. 2005
    ....
  37. ncbi request reprint The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Eur J Cancer 44:84-91. 2008
    ..To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone...
  38. ncbi request reprint Decrease of estrogen receptor expression and associated ERE-dependent transcription in MCF-7 breast cancer cells after oligomycin treatment
    Hye Sook Seo
    Laboratoire J C Heuson de Cancérologie Mammaire, Service de Medecine Interne, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Steroids 68:257-69. 2003
    ..Hence, phosphorylations/dephosphorylations of specific sites on ER and/or co-regulators seem to govern its turnover...
  39. ncbi request reprint Predictive molecular markers in the adjuvant therapy of breast cancer: state of the art in the year 2002
    Angelo Di Leo
    Department of Chemotherapy, Jules Bordet Institute, Brussels, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Int J Clin Oncol 7:245-53. 2002
    ..In the last part of the article, the most important findings have been summarized and future avenues of research have been outlined...
  40. doi request reprint [Has the time arrived for gene expression use at the bedside?]
    Véronique D'Hondt
    Service de Medecine Interne, Clinique d oncologie médicale, Institut Jules Bordet, 121, boulevard de Waterloo Bruxelles 1000, Belgique
    Bull Cancer 95:336-43. 2008
    ..Here we describe the state of the art of gene expression profiling for breast cancer, and we discuss the potential impact on breast cancer patient management considering its limits and promises...
  41. pmc Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays
    Christos Sotiriou
    Medicine Branch, Division of Clinical Sciences, National Cancer Institute, National Institutes of Health, Gaithersburg, Maryland, USA
    J Mol Diagn 4:30-6. 2002
    ..Pooling the core biopsies did not improve the concordance with excisional biopsies. In conclusion, our results suggest that core biopsies can be used as a suitable and reliable material for the determination of tumor genetic profiles...
  42. doi request reprint Better translation from bench to bedside: breakthroughs in the individualized treatment of cancer
    Carolyn Straehle
    Breast International Group, Brussels, Belgium
    Crit Care Med 37:S22-9. 2009
    ....
  43. ncbi request reprint Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)
    Rosa Giuliani
    Translational Research Unit, Jules Bordet Institute, 125, boulevard de Waterloo, 1000 Brussels, Belgium
    Eur J Cancer 43:725-35. 2007
    ....
  44. ncbi request reprint Targeting the ubiquitin-proteasome pathway in breast cancer
    Fatima Cardoso
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:148-57. 2004
    ....
  45. doi request reprint Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, B 1000 Brussels, Belgium
    Crit Rev Oncol Hematol 77:20-9. 2011
    ....
  46. ncbi request reprint Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade
    Sherene Loi
    Jules Bordet Institute Machine Learning Group, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 25:1239-46. 2007
    ..However, although the basal and the ErbB2 subtypes are repeatedly recognized, identification of estrogen receptor (ER) -positive subtypes has been inconsistent. Therefore, refinement of their molecular definition is needed...
  47. pmc HER2-positive circulating tumor cells in breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    PLoS ONE 6:e15624. 2011
    ..Tumor cell dissemination has been suggested to occur early in BC progression. To interrogate dissemination in BC, we studied CTCs and HER2 expression on CTCs across the spectrum of BC staging...
  48. ncbi request reprint Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
    Fatima Cardoso
    Translational Research Unit, Center for Education and Research in Food and Chemical Industry, Universite Libre de Bruxelles, Belgium
    Mol Cancer Ther 5:3042-51. 2006
    ....
  49. ncbi request reprint Potential predictive value of Bcl-2 for response to tamoxifen in the adjuvant setting of node-positive breast cancer
    Fatima Cardoso
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Clin Breast Cancer 5:364-9. 2004
    ..88) for Bcl-2-negative disease. Despite its being a retrospective nonrandomized study with a relatively low number of patients, our results suggest that Bcl-2 deserves further evaluation as a predictive factor of sensitivity to tamoxifen...
  50. pmc PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer
    Sherene Loi
    Department of Research, Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, East Melbourne 3002, Australia
    Proc Natl Acad Sci U S A 107:10208-13. 2010
    ..In ER+ BC cell lines, PIK3CA mutations were also associated with sensitivity to tamoxifen. These findings could have important implications for the treatment of PIK3CA-mutant BCs and the development of PI3K/mTOR inhibitors...
  51. doi request reprint Understanding the molecular basis of histologic grade
    M Ignatiadis
    Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
    Pathobiology 75:104-11. 2008
    ..In this same meta-analysis, proliferation was shown to be the common driving force responsible for the performance of various breast cancer prognostic signatures...
  52. ncbi request reprint Gene expression profiling in breast cancer
    C Sotiriou
    Instituet Jules Bordet, Medical Oncology Clinic, Brussels, Belgium
    Ann Oncol 17:x259-62. 2006
  53. doi request reprint Treatment of pT1N0 breast cancer: multigene predictors to assess risk of relapse
    D Fumagalli
    Jules Bordet Institute, Translational Research Unit, Universite Libre de Bruxelles, Bruxelles, Belgium
    Ann Oncol 21:vii103-6. 2010
    ..It is prospected that the greater accuracy of this new wave of predictors will provide substantial support to the existing decision tools and will significantly ameliorate our current ability to define breast cancer prognosis...
  54. ncbi request reprint Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients
    Christine Desmedt
    Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Int J Cancer 119:2539-45. 2006
    ....
  55. ncbi request reprint Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series
    Christine Desmedt
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Clin Cancer Res 13:3207-14. 2007
    ..The aims of this study conducted by TRANSBIG were to independently validate these results and to compare the outcome with clinical risk assessment...
  56. ncbi request reprint Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma
    Amir A Jazaeri
    Center for Cancer Research of the National Cancer Institute, Gaithersburg, Maryland, USA
    Mol Carcinog 36:53-9. 2003
    ..Dysregulation of centrosome function is one potential mechanistic link between genetic/epigenetic changes and the poorly differentiated phenotype in ovarian cancer...
  57. ncbi request reprint Proliferation: the most prominent predictor of clinical outcome in breast cancer
    Christine Desmedt
    Functional Genomics and Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    Cell Cycle 5:2198-202. 2006
    ..Importantly, their weight seems to be far more important in ER-positive than in ER-negative disease...
  58. doi request reprint Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of hypereosinophilic syndrome reveals targeting of growth control pathways
    Marie Ravoet
    Molecular Immunology Unit, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Blood 114:2969-83. 2009
    ....
  59. pmc Breast cancer classification and prognosis based on gene expression profiles from a population-based study
    Christos Sotiriou
    Division of Clinical Sciences, National Cancer Institute, Advanced Technology Center, 8717 Grovemont Circle, Gaithersburg, MD 20877, USA
    Proc Natl Acad Sci U S A 100:10393-8. 2003
    ..When taken together with other array studies, our results highlight the consistent biological and clinical associations with gene expression profiles...
  60. ncbi request reprint Breast cancer gene expression profiling: clinical trial and practice implications
    Sherene Loi
    Jules Bordet Institute, Microarray Laboratories, Department of Medical Oncology, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Pharmacogenomics 6:49-58. 2005
    ..This will lead, ultimately, to the application of user-friendly tools derived from this technology to everyday patient care...
  61. doi request reprint Change in the microenvironment of breast cancer studied by FTIR imaging
    S Kumar
    Laboratory for the Structure and Function of Biological Membranes, Center for Structural Biology and Bioinformatics, Universite Libre de Bruxelles, Campus Plaine CP 206 2 Bâtiment BC, Blvd du Triomphe, B 1050 Bruxelles, Belgium
    Analyst 138:4058-65. 2013
    ..This chemical imaging approach to analyze the breast cancer microenvironment could be used in the future for improving diagnostics of breast cancer...
  62. doi request reprint Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding
    M Verdonck
    Laboratory for the Structure and Function of Biological Membranes, Center for Structural Biology and Bioinformatics, Universite Libre de Bruxelles, Campus Plaine, Bld du Triomphe 2, CP206 2, B1050 Brussels, Belgium
    Analyst 138:4083-91. 2013
    ..This last result paves the way towards identification and characterization of cellular subtypes on FFPE tissue sections by FTIR imaging, indicating that this analysis technique could become a potential useful tool in cancer research...
  63. ncbi request reprint Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care?
    Christos Sotiriou
    Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, 1000 Brussels, Belgium
    Nat Rev Cancer 7:545-53. 2007
    ..We also discuss the potential of molecular signatures to have an impact on individual breast cancer patient management, and ultimately to accelerate the transition between empirical and tailored medicine...
  64. ncbi request reprint Understanding the biology of triple-negative breast cancer
    C Criscitiello
    Breast Cancer Translational Research Laboratory J C Heuson, Universite Libre de Bruxelles, Institut Jules Bordet, Brussels, Belgium
    Ann Oncol 23:vi13-8. 2012
    ..It is anticipated that a greater understanding of the biology of TNBC and its complex heterogeneity will reveal novel targets or identify markers around which clinical trials in molecularly well-defined sub-groups can be designed...
  65. ncbi request reprint Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer
    F Cardoso
    Translational Research Unit, Department of Medical Oncology, Jules Bordet Institute, 1000 Brussels, Belgium
    Int J Oncol 24:201-9. 2004
    ..iii) The role of combined evaluation of several relevant markers and of potential 'molecular signatures' are currently being evaluated in prospective randomized clinical trials...
  66. ncbi request reprint HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation
    H Akl
    Laboratory of Experimental Hematology, Bordet Institute, Faculty of Medicine, Universite Libre de Bruxelles, Brussels, Belgium
    Leukemia 21:788-96. 2007
    ..This could be a major event in the process of the malignant transformation into ATLL...
  67. ncbi request reprint Challenges in breast cancer clinical trial design in the postgenomic era
    Sherene Loi
    Translational Research Unit, Jules Bordet Institute, 121 Boulevard de Waterloo, Brussels 1000, Belgium
    Curr Opin Oncol 16:536-41. 2004
    ..The neoadjuvant setting presents a unique opportunity to test new concepts in a previously untreated patient population, because they may yield preliminary answers in a shorter time than that required in adjuvant trials...
  68. ncbi request reprint Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice
    Yan Ma
    Pathology Department, Institut Jules Bordet, Brussels, Belgium
    Clin Cancer Res 11:4393-9. 2005
    ..To assess the effect of chromosome 17 copy number on HER-2/neu status determination in breast cancers...
  69. ncbi request reprint Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer
    Lissandra Dal Lago
    Translational Research Unit, Bordet Institute, Brussels, Belgium
    Mol Cancer Ther 5:2572-9. 2006
    ..This project aimed to determine the optimal scoring method for fluorescence in situ hybridization (FISH) assay...
  70. doi request reprint Circulating tumor cells and emerging blood biomarkers in breast cancer
    Carmen Criscitiello
    Medical Oncology Department, Jules Bordet Institute, Brussels, Belgium
    Curr Opin Oncol 22:552-8. 2010
    ..To critically review the latest findings concerning the role of circulating tumor cells (CTCs) and other blood biomarkers in breast cancer...
  71. ncbi request reprint New tools for assessing breast cancer recurrence
    Phuong Dinh
    Department of Medical Oncology, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Res 141:99-118. 2008
  72. ncbi request reprint Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation
    Phillipe Lothaire
    Department of Surgery, Institut Jules Bordet, Brussels, Belgium
    Head Neck 28:256-69. 2006
    ..The aim of this article is to review recent developments in the biological understanding of head and neck squamous cell carcinomas...
  73. pmc Decoding the evolution of a breast cancer genome
    Philippe L Bedard
    Department of Medical Oncology, Jules Bordet Institute, Brussels, Belgium
    EMBO Mol Med 2:3-5. 2010
    ..Philippe Bedard and Christos Sotiriou analyse their findings as well as the challenges of applying the study of cancer genomes to clinical cancer care...
  74. pmc Defining the galaxy of gene expression in breast cancer
    Edison T Liu
    Genome Institute of Singapore, 1 Science Park Road, 05 01 Science Park II, Singapore
    Breast Cancer Res 4:141-4. 2002
    ..These principles are examined and the impact of these results on understanding the biology and the clinical behaviour of breast tumors is explored...
  75. ncbi request reprint Molecular profiles of invasive mucinous and ductal carcinomas of the breast: a molecular case study
    Lajos Pusztai
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Genet Cytogenet 141:148-53. 2003
    ..Taken together, these data suggest that expression profiling can be used diagnostically to distinguish individual histologic subclassifications and may guide the selection of target therapeutics...
  76. doi request reprint A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer
    Xiao Jun Ma
    AviaraDx, Inc, San Diego, California, USA
    Clin Cancer Res 14:2601-8. 2008
    ....
  77. pmc Evaluation of biological pathways involved in chemotherapy response in breast cancer
    Attila Tordai
    Department of Breast Medical Oncology, The University of Texas M, d, Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    Breast Cancer Res 10:R37. 2008
    ..Our goal was to examine the association between biological pathways and response to chemotherapy in estrogen receptor-positive (ER+) and ER-negative (ER-) breast tumors separately...
  78. doi request reprint hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer
    Carme Camps
    Genomics Group, Wellcome Trust Centre for Human Genetics, The Henry Wellcome Building for Genomic Medicine, University of Oxford, Oxford, United Kingdom
    Clin Cancer Res 14:1340-8. 2008
    ..We examined hypoxia-induced miRNA expression changes to identify markers of survival in breast cancer...
  79. ncbi request reprint Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer
    Fabrice Andre
    Breast Cancer Unit and Translational Research Unit, UPRES03535, Institut Gustave Roussy, Villejuif, France
    Clin Cancer Res 13:2061-7. 2007
    ..A molecular marker may be prognostic of outcome or predictive of response to therapy, or a combination of both...
  80. ncbi request reprint Molecular forecasting of breast cancer: time to move forward with clinical testing
    Sherene Loi
    J Clin Oncol 24:721-2; author reply 722-3. 2006
  81. doi request reprint Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, Crete, Greece
    Clin Breast Cancer 7:883-9. 2007
    ..The aim of this study was to evaluate the clinical relevance of the simultaneous detection of cytokeratin (CK)-19 messenger RNA (mRNA)- and HER2 mRNA-positive cells in peripheral blood of women with early-stage breast cancer...
  82. ncbi request reprint Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, PO Box 1352, Heraklion 711 10, Crete, Greece
    J Clin Oncol 25:5194-202. 2007
    ..To examine the prognostic value of cytokeratin-19 (CK-19) mRNA-positive circulating tumor cells (CTCs) in early-stage breast cancer patients focusing on clinically relevant subgroups based on estrogen receptor (ER) and HER2 expression...
  83. ncbi request reprint Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study
    Yun Gong
    Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 8:203-11. 2007
    ..Our goal was to establish a new method to assign oestrogen receptor and ERBB2-receptor status to breast carcinoma based on mRNA expression measured using Affymetrix U133A gene-expression profiling...
  84. doi request reprint Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes
    Christine Desmedt
    Medical Oncology Department, Jules Bordet Institute
    Clin Cancer Res 14:5158-65. 2008
    ..Here we aimed to perform a comprehensive meta-analysis integrating both clinicopathologic and gene expression data, focusing on the main molecular subtypes...
  85. pmc Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells
    Pavel Klener
    Laboratory of Experimental Hematology, Bordet Institute, 121 Blvd de Waterloo, 1000 Brussels, Belgium
    J Virol 80:1922-38. 2006
    ....